Vital Therapies

Vital Therapies, Inc. is a biotherapeutic company focused on developing a cell-based therapy targeting the treatment of acute liver failure. Our product candidate, the ELAD® System, or ELAD, is a bio-artificial liver therapy that operates outside the body, or extracorporeal, and is designed with the proposed intent to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. ELAD is an allogeneic cellular therapy system incorporating our human liver-derived C3A cells contained in four hollow fiber cartridges that are combined with a single use customized disposable set and a reusable bedside unit. Data from ELAD clinical studies has shown trends that may indicate a potential to increase survival rates in patients with acute liver failure. ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure. Prior to the initiation of our ongoing Phase III clinical trial program, more than 150 subjects have received ELAD therapy in seven clinical trials and through a compassionate use program, which we believe collectively suggests a promising therapeutic profile. We are currently initiating three Phase III clinical trials in various acute liver failure conditions. In March 2013, we initiated VTI-208, a Phase III randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation. In the fourth quarter of 2013, we intend to initiate two additional Phase III randomized controlled trials, VTI-210, in 120 subjects with acute alcoholic hepatitis, and VTI-212, in 126 subjects with fulminant hepatic failure.

Type
Public
HQ
San Diego, US
Founded
2003
Employees
78 (est)
Vital Therapies was founded in 2003 and is headquartered in San Diego, US

Key People at Vital Therapies

Ross A. Jaffe

Ross A. Jaffe

Director
John Brotherton

John Brotherton

VP, Research & Developmen
Shapour Asslani

Shapour Asslani

VP, Quality Control & Quality Assurance
Robert A. Ashley

Robert A. Ashley

Chief Operating Officer, Executive Vice President
Duane Nash

Duane Nash

EVP
Dar He

Dar He

Vice President, International Operations

Vital Therapies Locations

San Diego, US

Vital Therapies Metrics

Vital Therapies Summary

Market capitalization

$167 M

Closing share price

$5.3
Vital Therapies's latest market capitalization is $167 M.

Vital Therapies Market Value History

Vital Therapies News

Vital Therapies Company Life

You may also be interested in